GlaxoSmithKline, that’s who.
Another drug, another round of heretofore unknown side effects. Well…not exactly unknown. Are we really surprised?
Avandia made a big splash recently because the popular type 2 diabetes drug was linked to an increased risk for serious heart problems. It gets better: the new news on Avandia shows that had doctors been adequately made aware of the potential trouble and therefore accurately reported related heart trouble in their diabetic patients, the entire eight year debacle would have likely been prevented. Instead, as you’d expect, we’re suddenly seeing a tripling of heart problems being reported in relation to Avandia. It’s yet another unnecessary slew of health problems thanks to a drug that needed better safety guidelines, and it’s yet another case for greater pharmaceutical transparency. But most of all it’s a case for prevention of the disease in the first place.
Have you been touched by diabetes?
No? Give it a month.
The best part about all of this: Avandia is primarily used to treat cases of type 2 stemming from (wait for it) obesity. We’ve managed to create an egregiously successful obesity epidemic and millions of cases of designer diabetes thanks to garbage fare along the likes of the Bees’ weekend trip to the middle aisles of the grocery store.
I wonder: for all the billions spent shilling and spilling Avandia all over the place, how many health education classes and nutritious food subsidies could have been given to obese, diabetic patients instead?
Note: I’m not bagging on TU – what’s got me in a twist is the fact that we even need organizations like this.